| Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial F Mosele, E Deluche, A Lusque, L Le Bescond, T Filleron, Y Pradat, ... Nature medicine 29 (8), 2110-2120, 2023 | 88 | 2023 |
| LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial MF Mosele, A Lusque, V Dieras, E Deluche, A Ducoulombier, B Pistilli, ... Annals of Oncology 33, S123, 2022 | 53 | 2022 |
| Mechanism of action and resistance to trastuzumab deruxtecan in patients with metastatic breast cancer: the DAISY trial F Andre, M Fernanda, E Deluche, A LUSQUE, L Le-Bescond, T Filleron, ... | 6 | 2022 |
| Unsupervised nuclei segmentation using spatial organization priors L Le Bescond, M Lerousseau, I Garberis, F André, S Christodoulidis, ... International Conference on Medical Image Computing and Computer-Assisted …, 2022 | 3 | 2022 |
| 171P A deep learning model for breast cancer diagnosis from fine-needle aspiration cytology whole slide images L Le Bescond, V Suciu, S Christodoulidis, M Vakalopoulou, HG Talbot, ... ESMO Open 9, 2024 | | 2024 |
| SparseXMIL: Leveraging spatial context for classifying whole slide images in digital pathology L Le Bescond, M Lerousseau, F Andre, H Talbot | | 2024 |
| On the detection of Out-Of-Distribution samples in Multiple Instance Learning LL Bescond, M Vakalopoulou, S Christodoulidis, F Andre, H Talbot arXiv preprint arXiv:2309.05528, 2023 | | 2023 |
